Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04895748
Title	DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	clear cell renal cell carcinoma
Therapies	DFF332 + Spartalizumab + Taminadenant DFF332 + Everolimus DFF332
Age Groups:	adult \| child \| senior
Covered Countries	USA \| ITA \| FRA \| ESP \| CZE